{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:29:30Z","timestamp":1791923370228,"version":"4.3.4"},"reference-count":117,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Obesity is a rapidly growing epidemic affecting &amp;gt;15% of the global adult population and has considerable clinical consequences and comorbidities, including hypertension, diabetes mellitus, cardiovascular and cerebrovascular diseases and chronic kidney disease. There is a strong association between obesity or body mass index and high blood pressure (BP) in epidemiological studies while the underlying pathophysiological events linking those conditions are not fully elucidated. Hypothetical mechanisms include a sedentary lifestyle and excess intake of processed foods that contribute to obesity, overactivation of the renin\u2013angiotensin\u2013aldosterone and sympathetic nervous systems, inflammation, altered adipokine homeostasis and the fatty kidney hypothesis involving adipose tissue accumulation in the renal sinus and perirenal space. There are multiple pharmacotherapeutic and surgical approaches for the management of obesity, including dual and triple agonist drugs targeting glucagon-like peptide-1, gastric inhibitory peptide and glucagon receptors and endoscopic bariatric procedures. Despite promising results with such therapeutic approaches in terms of body weight reduction and BP control, it is unclear whether such BP reduction may completely be attributable to weight loss. Confirmation of the adiposity dependence would lead to a major paradigm shift in our understanding of hypertension, potentially leading to a major shift in the causes of hypertension from primary hypertension to adiposity-dependent hypertension, leading to a shift from symptomatic treatment with antihypertensive medication to cause-focused treatment with weight loss medication. In this narrative review, the aim is to evaluate the potential pathophysiological mechanisms linking hypertension and obesity and the efficiency of potential therapeutic approaches on BP.<\/jats:p>","DOI":"10.1093\/ckj\/sfaf218","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T07:37:47Z","timestamp":1751960267000},"source":"Crossref","is-referenced-by-count":10,"title":["From pathophysiology to novel approaches for obesity-associated hypertension"],"prefix":"10.1093","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1297-0675","authenticated-orcid":false,"given":"Mehmet","family":"Kanbay","sequence":"first","affiliation":[{"name":"Section of Nephrology, Ko\u00e7 University School of Medicine Department of Medicine, , Istanbul ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif","family":"Yayci","sequence":"additional","affiliation":[{"name":"Ko\u00e7 University School of Medicine Department of Medicine, , Istanbul ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candan","family":"Genc","sequence":"additional","affiliation":[{"name":"Ko\u00e7 University School of Medicine Department of Medicine, , Istanbul ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidar","family":"Copur","sequence":"additional","affiliation":[{"name":"Ko\u00e7 University School of Medicine Department of Medicine, , Istanbul ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozgur","family":"Aktas","sequence":"additional","affiliation":[{"name":"Ko\u00e7 University School of Medicine Department of Medicine, , Istanbul ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9174-4018","authenticated-orcid":false,"given":"Pantelis","family":"Sarafidis","sequence":"additional","affiliation":[{"name":"Hippokration Hospital, Aristotle University of Thessaloniki First Department of Nephrology, , Thessaloniki ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Covic","sequence":"additional","affiliation":[{"name":"Nephrology Clinic, Dialysis, and Renal Transplant Center, \u201cC.I. Parhon\u201d University Hospital , Iasi ,","place":["Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9805-9523","authenticated-orcid":false,"given":"Alberto","family":"Ortiz","sequence":"additional","affiliation":[{"name":"Universidad Autonoma de Madrid and IIS-Fundacion Jimenez Diaz Department of Medicine, , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke J","family":"Laffin","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Foundation Section of Preventive Cardiology and Rehabilitation, Department of Cardiovascular Medicine, , Cleveland, OH ,","place":["USA"]},{"name":"Cleveland Clinic Coordinating Center for Clinical Research, Cleveland Clinic Foundation , Cleveland, OH ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,9]]},"reference":[{"key":"2025080406164114700_bib1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1614362","article-title":"Health effects of overweight and obesity in 195 countries over 25 years","volume":"377","author":"Afshin","year":"2017","journal-title":"N Engl J Med"},{"key":"2025080406164114700_bib2","doi-asserted-by":"publisher","first-page":"101850","DOI":"10.1016\/j.eclinm.2023.101850","article-title":"Trends and predictions of malnutrition and obesity in 204 countries and territories: an analysis of the Global Burden of Disease Study 2019","volume":"57","author":"Chong","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"7 Suppl","key":"2025080406164114700_bib3","first-page":"s176","article-title":"Obesity: definition, comorbidities, causes, and burden","volume":"22","author":"Apovian","year":"2016","journal-title":"Am J Manag Care"},{"key":"2025080406164114700_bib4","doi-asserted-by":"publisher","first-page":"12305","DOI":"10.3390\/ijms232012305","article-title":"Hypertension related to obesity: pathogenesis, characteristics and factors for control","volume":"23","author":"El Meouchy","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2025080406164114700_bib5","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1161\/CIRCRESAHA.116.305697","article-title":"Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms","volume":"116","author":"Hall","year":"2015","journal-title":"Circ Res"},{"key":"2025080406164114700_bib6","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.amjhyper.2004.05.017","article-title":"Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled","volume":"17","author":"Bramlage","year":"2004","journal-title":"Am J Hypertens"},{"key":"2025080406164114700_bib7","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1161\/01.HYP.36.4.594","article-title":"Differential control of systolic and diastolic blood pressure: factors associated with lack of blood pressure control in the community","volume":"36","author":"Lloyd-Jones","year":"2000","journal-title":"Hypertension"},{"key":"2025080406164114700_bib8","doi-asserted-by":"publisher","first-page":"102355","DOI":"10.1016\/j.coph.2023.102355","article-title":"The blood pressure lowering effects of glucagon-like peptide-1 receptor agonists: a mini-review of the potential mechanisms","volume":"69","author":"Ribeiro-Silva","year":"2023","journal-title":"Curr Opin Pharmacol"},{"key":"2025080406164114700_bib9","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.jacc.2023.11.032","article-title":"Randomized trial of effect of bariatric surgery on blood pressure after 5 years","volume":"83","author":"Schiavon","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2025080406164114700_bib10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mce.2012.06.021","article-title":"Adipose tissue renin-angiotensin-aldosterone system (RAAS) and progression of insulin resistance","volume":"378","author":"Marcus","year":"2013","journal-title":"Mol Cell Endocrinol"},{"key":"2025080406164114700_bib11","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s00285-023-01891-y","article-title":"The intrarenal renin-angiotensin system in hypertension: insights from mathematical modelling","volume":"86","author":"Smith","year":"2023","journal-title":"J Math Biol"},{"key":"2025080406164114700_bib12","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1097\/00004872-200309000-00027","article-title":"Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study","volume":"21","author":"Grassi","year":"2003","journal-title":"J Hypertens"},{"key":"2025080406164114700_bib13","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1097\/HJH.0b013e32835b6c02","article-title":"Differential effects of renin-angiotensin-aldosterone system inhibition, sympathoinhibition and diuretic therapy on endothelial function and blood pressure in obesity-related hypertension: a double-blind, placebo-controlled cross-over trial","volume":"31","author":"Dorresteijn","year":"2013","journal-title":"J Hypertens"},{"key":"2025080406164114700_bib14","doi-asserted-by":"publisher","first-page":"115","DOI":"10.4239\/wjd.v11.i4.115","article-title":"Novel insight into perirenal adipose tissue: a neglected adipose depot linking cardiovascular and chronic kidney disease","volume":"11","author":"Huang","year":"2020","journal-title":"World J Diabetes"},{"key":"2025080406164114700_bib15","doi-asserted-by":"publisher","first-page":"e13748","DOI":"10.1111\/eci.13748","article-title":"Fatty kidney: a possible future for chronic kidney disease research","volume":"52","author":"Kanbay","year":"2022","journal-title":"Eur J Clin Invest"},{"key":"2025080406164114700_bib16","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/s41581-019-0145-4","article-title":"Obesity, kidney dysfunction and hypertension: mechanistic links","volume":"15","author":"Hall","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"2025080406164114700_bib17","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/nrneph.2009.184","article-title":"An update on the lipid nephrotoxicity hypothesis","volume":"5","author":"Ruan","year":"2009","journal-title":"Nat Rev Nephrol"},{"key":"2025080406164114700_bib18","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/ncpneph1022","article-title":"The role of obesity in the pathogenesis of hypertension","volume":"5","author":"Bogaert","year":"2009","journal-title":"Nat Rev Nephrol"},{"key":"2025080406164114700_bib19","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1161\/01.CIR.89.6.2634","article-title":"Body fat and sympathetic nerve activity in healthy subjects","volume":"89","author":"Scherrer","year":"1994","journal-title":"Circulation"},{"key":"2025080406164114700_bib20","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1161\/01.HYP.36.4.538","article-title":"Adrenergic and reflex abnormalities in obesity-related hypertension","volume":"36","author":"Grassi","year":"2000","journal-title":"Hypertension"},{"key":"2025080406164114700_bib21","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1161\/01.HYP.23.6.1059","article-title":"Anteroventral third ventricle lesions abolish lumbar sympathetic responses to insulin","volume":"23","author":"Muntzel","year":"1994","journal-title":"Hypertension"},{"key":"2025080406164114700_bib22","doi-asserted-by":"publisher","first-page":"17271","DOI":"10.1074\/jbc.R110.113175","article-title":"Obesity-induced hypertension: role of sympathetic nervous system, leptin, and melanocortins","volume":"285","author":"Hall","year":"2010","journal-title":"J Biol Chem"},{"key":"2025080406164114700_bib23","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1161\/01.HYP.0000242642.42177.49","article-title":"Mechanisms of sympathetic activation in obesity-related hypertension","volume":"48","author":"Esler","year":"2006","journal-title":"Hypertension"},{"key":"2025080406164114700_bib24","doi-asserted-by":"publisher","first-page":"R803","DOI":"10.1152\/ajpregu.00707.2003","article-title":"Obesity and hypertension: two epidemics or one?","volume":"286","author":"Davy","year":"2004","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"2025080406164114700_bib25","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2147\/IJNRD.S39739","article-title":"Obesity, hypertension, and chronic kidney disease","volume":"7","author":"Hall","year":"2014","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"2025080406164114700_bib26","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/j.1748-1716.2010.02171.x","article-title":"Role of adipokines in obesity-associated hypertension","volume":"200","author":"Vlasova","year":"2010","journal-title":"Acta Physiol (Oxf)"},{"key":"2025080406164114700_bib27","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2147\/vhrm.2006.2.2.163","article-title":"Leptin and hypertension in obesity","volume":"2","author":"Bravo","year":"2006","journal-title":"Vasc Health Risk Manag"},{"key":"2025080406164114700_bib28","doi-asserted-by":"publisher","first-page":"1365183","DOI":"10.3389\/fmed.2024.1365183","article-title":"Adipocentric origin of the common cardiometabolic complications of obesity in the young up to the very old: pathophysiology and new therapeutic opportunities","volume":"11","author":"Sarzani","year":"2024","journal-title":"Front Med"},{"key":"2025080406164114700_bib29","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1161\/HYPERTENSIONAHA.110.161349","article-title":"Control of blood pressure, appetite, and glucose by leptin in mice lacking leptin receptors in proopiomelanocortin neurons","volume":"57","author":"do Carmo","year":"2011","journal-title":"Hypertension"},{"key":"2025080406164114700_bib30","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/j.cell.2014.10.058","article-title":"Leptin mediates the increase in blood pressure associated with obesity","volume":"159","author":"Simonds","year":"2014","journal-title":"Cell"},{"key":"2025080406164114700_bib31","doi-asserted-by":"publisher","first-page":"R47","DOI":"10.1530\/JOE-16-0273","article-title":"Modeling the impact of growth and leptin deficits on the neuronal regulation of blood pressure","volume":"231","author":"Steinbrekera","year":"2016","journal-title":"J Endocrinol"},{"key":"2025080406164114700_bib32","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1042\/CS20070347","article-title":"Vascular effects of adiponectin: molecular mechanisms and potential therapeutic intervention","volume":"114","author":"Zhu","year":"2008","journal-title":"Clin Sci (Lond)"},{"key":"2025080406164114700_bib33","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1161\/HYPERTENSIONAHA.113.01453","article-title":"Adiponectin levels and the risk of hypertension: a systematic review and meta-analysis","volume":"62","author":"Kim","year":"2013","journal-title":"Hypertension"},{"key":"2025080406164114700_bib34","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1017\/S0029665112000092","article-title":"Obesity, inflammation and the immune system","volume":"71","author":"de Heredia","year":"2012","journal-title":"Proc Nutr Soc"},{"key":"2025080406164114700_bib35","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/1440-1681.12712","article-title":"Antihypertensive methyldopa, labetalol, hydralazine, and clonidine reversed tumour necrosis factor-\u03b1 inhibited endothelial nitric oxide synthase expression in endothelial-trophoblast cellular networks","volume":"44","author":"Xu","year":"2017","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"2025080406164114700_bib36","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.freeradbiomed.2022.01.020","article-title":"Elabela alleviates ferroptosis, myocardial remodeling, fibrosis and heart dysfunction in hypertensive mice by modulating the IL-6\/STAT3\/GPX4 signaling","volume":"181","author":"Zhang","year":"2022","journal-title":"Free Radic Biol Med"},{"key":"2025080406164114700_bib37","doi-asserted-by":"publisher","first-page":"156226","DOI":"10.1016\/j.cyto.2023.156226","article-title":"Colorable role of interleukin (IL)-6 in obesity hypertension: a hint from a Chinese adult case-control study","volume":"168","author":"Wu","year":"2023","journal-title":"Cytokine"},{"key":"2025080406164114700_bib38","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1161\/CIRCRESAHA.119.312321","article-title":"Obesity, hypertension, and cardiac dysfunction: novel roles of immunometabolism in macrophage activation and inflammation","volume":"126","author":"Mouton","year":"2020","journal-title":"Circ Res"},{"key":"2025080406164114700_bib39","doi-asserted-by":"publisher","first-page":"F442","DOI":"10.1152\/ajprenal.00335.2004","article-title":"Regulation of the renal thiazide-sensitive Na-Cl cotransporter, blood pressure, and natriuresis in obese Zucker rats treated with rosiglitazone","volume":"289","author":"Khan","year":"2005","journal-title":"Am J Physiol Renal Physiol"},{"key":"2025080406164114700_bib40","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1159\/000368527","article-title":"The thiazide-sensitive co-transporter promotes the development of sodium retention in mice with diet-induced obesity","volume":"40","author":"Davies","year":"2015","journal-title":"Kidney Blood Press Res"},{"key":"2025080406164114700_bib41","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1097\/MAJ.0b013e31825ce50f","article-title":"Risk factors associated with antihypertensive medication nonadherence in a statewide Medicaid population","volume":"348","author":"Bailey","year":"2014","journal-title":"Am J Med Sci"},{"key":"2025080406164114700_bib42","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1007\/s11886-017-0912-4","article-title":"Hypertension in obesity and the impact of weight loss","volume":"19","author":"Cohen","year":"2017","journal-title":"Curr Cardiol Rep"},{"key":"2025080406164114700_bib43","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/s41581-021-00399-2","article-title":"Kidney and epigenetic mechanisms of salt-sensitive hypertension","volume":"17","author":"Kawarazaki","year":"2021","journal-title":"Nat Rev Nephrol"},{"key":"2025080406164114700_bib44","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1001\/jama.2023.16029","article-title":"Aldosterone synthase inhibition with lorundrostat for uncontrolled hypertension: the Target-HTN randomized clinical trial","volume":"330","author":"Laffin","year":"2023","journal-title":"JAMA"},{"key":"2025080406164114700_bib45","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2501440","article-title":"Lorundrostat efficacy and safety in patients with uncontrolled hypertension","volume":"392","author":"Laffin","year":"2025","journal-title":"N Engl J Med"},{"key":"2025080406164114700_bib46","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.1172\/JCI43124","article-title":"Rac1 GTPase in rodent kidneys is essential for salt-sensitive hypertension via a mineralocorticoid receptor-dependent pathway","volume":"121","author":"Shibata","year":"2011","journal-title":"J Clin Invest"},{"key":"2025080406164114700_bib47","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1161\/HYPERTENSIONAHA.107.091058","article-title":"Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor: role of oxidative stress","volume":"50","author":"Nagase","year":"2007","journal-title":"Hypertension"},{"key":"2025080406164114700_bib48","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1056\/NEJM198908313210905","article-title":"The effect of weight loss on the sensitivity of blood pressure to sodium in obese adolescents","volume":"321","author":"Rocchini","year":"1989","journal-title":"N Engl J Med"},{"key":"2025080406164114700_bib49","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41371-019-0239-2","article-title":"The combination of obesity and high salt intake are associated with blood pressure elevation among healthy Japanese adolescents","volume":"34","author":"Sougawa","year":"2020","journal-title":"J Hum Hypertens"},{"key":"2025080406164114700_bib50","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/j.1524-6175.2003.02029.x","article-title":"Response to six classes of antihypertensive medications by body mass index in a randomized controlled trial","volume":"5","author":"Materson","year":"2003","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2025080406164114700_bib51","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1159\/000514346","article-title":"A stronger effect of body mass index and waist circumference on the prevalence of uncontrolled hypertension among Caucasian men than women","volume":"46","author":"Chudek","year":"2021","journal-title":"Kidney Blood Press Res"},{"key":"2025080406164114700_bib52","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2165\/11318100-000000000-00000","article-title":"Effect of obesity on the pharmacokinetics of drugs in humans","volume":"49","author":"Hanley","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"2025080406164114700_bib53","first-page":"109","article-title":"The effect of weight, body mass index, age, sex, and race on plasma concentrations of subcutaneous sumatriptan: a pooled analysis","volume":"8","author":"Munjal","year":"2016","journal-title":"Clin Pharmacol"},{"key":"2025080406164114700_bib54","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/bdd.357","article-title":"Comparative pharmacokinetics and pharmacodynamics of propranolol and atenolol in normolipaemic and hyperlipidaemic obese subjects","volume":"24","author":"W\u00f3jcicki","year":"2003","journal-title":"Biopharm Drug Disp"},{"key":"2025080406164114700_bib55","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/S0895-7061(01)01293-6","article-title":"Antihypertensive effect of \u03b1- and \u03b2-adrenergic blockade in obese and lean hypertensive subjects","volume":"14","author":"Wofford","year":"2001","journal-title":"Am J Hypertens"},{"key":"2025080406164114700_bib56","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s002280050237","article-title":"Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects","volume":"51","author":"Cheymol","year":"1997","journal-title":"Eur J Clin Pharmacol"},{"key":"2025080406164114700_bib57","doi-asserted-by":"crossref","first-page":"115281","DOI":"10.1016\/j.biopha.2023.115281","article-title":"Pharmacokinetics of obese adults: not only an increase in weight","volume":"166","author":"Gouju","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"2025080406164114700_bib58","doi-asserted-by":"crossref","first-page":"sfad282","DOI":"10.1093\/ckj\/sfad282","article-title":"Mechanisms and treatment of obesity-related hypertension\u2014part 1: mechanisms","volume":"17","author":"Parvanova","year":"2023","journal-title":"Clin Kidney J"},{"key":"2025080406164114700_bib59","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1042\/CS20040238","article-title":"Change in beta1-adrenergic receptor protein concentration in adipose tissue correlates with diet-induced weight loss","volume":"108","author":"Rasmussen","year":"2005","journal-title":"Clin Sci (Lond)"},{"key":"2025080406164114700_bib60","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2165\/00003088-200039030-00004","article-title":"Effects of obesity on pharmacokinetics implications for drug therapy","volume":"39","author":"Cheymol","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"2025080406164114700_bib61","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S0140-6736(14)61171-5","article-title":"Effects of blood pressure lowering on cardiovascular risk according to baseline body-mass index: a meta-analysis of randomised trials","volume":"385","author":"Ying","year":"2015","journal-title":"Lancet"},{"key":"2025080406164114700_bib62","doi-asserted-by":"crossref","first-page":"102789","DOI":"10.1016\/j.eclinm.2024.102789","article-title":"GLP-1-based therapies for the treatment of resistant hypertension in individuals with overweight or obesity: a review","volume":"75","author":"Jarade","year":"2024","journal-title":"eClinicalMedicine"},{"key":"2025080406164114700_bib63","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1038\/oby.2010.35","article-title":"Disparity in physician perception of patients\u2019 adherence to medications by obesity status","volume":"18","author":"Huizinga","year":"2010","journal-title":"Obesity (Silver Spring)"},{"key":"2025080406164114700_bib64","doi-asserted-by":"publisher","first-page":"101882","DOI":"10.1016\/j.eclinm.2023.101882","article-title":"Pharmacotherapy of obesity: an update on the available medications and drugs under investigation","volume":"58","author":"Chakhtoura","year":"2023","journal-title":"eClinicalMedicine"},{"key":"2025080406164114700_bib65","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/jch.12049","article-title":"Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment: a position paper of the Obesity Society and the American Society of Hypertension","volume":"15","author":"Landsberg","year":"2013","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2025080406164114700_bib66","first-page":"751","article-title":"Hemodynamic effect of a single dose of glucagon-like peptide 1 receptor (GLP-1R) agonist liraglutide in patients with diabetic kidney disease","volume":"72","author":"Wajdlich","year":"2021","journal-title":"J Physiol Pharmacol"},{"key":"2025080406164114700_bib67","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/dom.12085","article-title":"Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials","volume":"15","author":"Wang","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"2025080406164114700_bib68","doi-asserted-by":"publisher","first-page":"e001986","DOI":"10.1136\/bmjopen-2012-001986","article-title":"Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis","volume":"3","author":"Robinson","year":"2013","journal-title":"BMJ Open"},{"key":"2025080406164114700_bib69","doi-asserted-by":"publisher","first-page":"772","DOI":"10.3390\/jcm12030772","article-title":"The effect of semaglutide on blood pressure in patients without diabetes: a systematic review and meta-analysis","volume":"12","author":"Kennedy","year":"2023","journal-title":"J Clin Med"},{"key":"2025080406164114700_bib70","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"2025080406164114700_bib71","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/S0140-6736(24)01498-3","article-title":"Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial","volume":"404","author":"Deanfield","year":"2024","journal-title":"Lancet"},{"key":"2025080406164114700_bib72","doi-asserted-by":"publisher","first-page":"ii19","DOI":"10.1093\/ckj\/sfae296","article-title":"GLP-1 receptor agonists in patients with chronic kidney disease and either overweight or obesity","volume":"17","author":"Abasheva","year":"2024","journal-title":"Clin Kidney J"},{"key":"2025080406164114700_bib73","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1056\/NEJMoa2302392","article-title":"Daily oral GLP-1 receptor agonist orforglipron for adults with obesity","volume":"389","author":"Wharton","year":"2023","journal-title":"N Engl J Med"},{"key":"2025080406164114700_bib74","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ejim.2023.04.005","article-title":"Tirzepatide decreases systolic and diastolic blood pressure","volume":"114","author":"Copur","year":"2023","journal-title":"Eur J Intern Med"},{"key":"2025080406164114700_bib75","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1007\/s11096-024-01779-x","article-title":"Efficacy and safety of tirzepatide versus placebo in overweight or obese adults without diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"46","author":"Liu","year":"2024","journal-title":"Int J Clin Pharm"},{"key":"2025080406164114700_bib76","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1161\/HYPERTENSIONAHA.123.22022","article-title":"Tirzepatide reduces 24-hour ambulatory blood pressure in adults with body mass index \u226527\u00a0kg\/m2: SURMOUNT-1 ambulatory blood pressure monitoring substudy","volume":"81","author":"de Lemos","year":"2024","journal-title":"Hypertension"},{"key":"2025080406164114700_bib77","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S2213-8587(22)00188-7","article-title":"Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial","volume":"10","author":"Inagaki","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025080406164114700_bib78","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1007\/s00125-023-05947-y","article-title":"100 years of glucagon and 100 more","volume":"66","author":"Wewer Albrechtsen","year":"2023","journal-title":"Diabetologia"},{"key":"2025080406164114700_bib79","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1016\/j.jhep.2023.07.033","article-title":"Incretins (GLP-1 receptor agonists and dual\/triple agonists) and the liver","volume":"79","author":"Newsome","year":"2023","journal-title":"J Hepatol"},{"key":"2025080406164114700_bib80","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"A phase 2 randomized trial of survodutide in MASH and fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"N Engl J Med"},{"key":"2025080406164114700_bib81","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1007\/s00125-023-06053-9","article-title":"Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon\/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial","volume":"67","author":"Bl\u00fcher","year":"2024","journal-title":"Diabetologia"},{"key":"2025080406164114700_bib82","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S2213-8587(23)00356-X","article-title":"Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial","volume":"12","author":"le Roux","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025080406164114700_bib83","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1038\/s41591-024-03018-2","article-title":"Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial","volume":"30","author":"Sanyal","year":"2024","journal-title":"Nat Med"},{"key":"2025080406164114700_bib84","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/S0140-6736(23)01053-X","article-title":"Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA","volume":"402","author":"Rosenstock","year":"2023","journal-title":"Lancet"},{"key":"2025080406164114700_bib85","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone-receptor agonist retatrutide for obesity\u2014a phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N Engl J Med"},{"issue":"13 Suppl","key":"2025080406164114700_bib86","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1016\/S0735-1097(24)03870-1","article-title":"The effect of triple-hormone-receptor agonist retatrutide, a novel medication for weight loss, on blood pressure\u2014a meta-analysis of randomized controlled phase 2 trials","volume":"83","author":"Kommu","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2025080406164114700_bib87","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1161\/CIRCRESAHA.116.307591","article-title":"Treatment of obesity: weight loss and bariatric surgery","volume":"118","author":"Wolfe","year":"2016","journal-title":"Circ Res"},{"key":"2025080406164114700_bib88","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1038\/s41440-023-01180-7","article-title":"Comparison of hypertension remission and relapse after sleeve gastrectomy and one-anastomosis gastric bypass: a prospective cohort study","volume":"46","author":"Ebadinejad","year":"2023","journal-title":"Hypertens Res"},{"key":"2025080406164114700_bib89","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1007\/s11695-019-04183-x","article-title":"Comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy on weight loss, weight regain, and remission of comorbidities: a 5 years of follow-up study","volume":"30","author":"Toolabi","year":"2020","journal-title":"Obes Surg"},{"key":"2025080406164114700_bib90","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1001\/jama.2017.20313","article-title":"Effect of laparoscopic sleeve gastrectomy vs laparoscopic Roux-en-Y gastric bypass on weight loss at 5 years among patients with morbid obesity: the SLEEVEPASS randomized clinical trial","volume":"319","author":"Salminen","year":"2018","journal-title":"JAMA"},{"key":"2025080406164114700_bib91","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1161\/HYPERTENSIONAHA.118.12290","article-title":"Effects of bariatric surgery versus medical therapy on the 24-hour ambulatory blood pressure and the prevalence of resistant hypertension: the GATEWAY randomized clinical trial","volume":"73","author":"Schiavon","year":"2019","journal-title":"Hypertension"},{"key":"2025080406164114700_bib92","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1001\/jama.292.14.1724","article-title":"Bariatric surgery: a systematic review and meta-analysis","volume":"292","author":"Buchwald","year":"2004","journal-title":"JAMA"},{"key":"2025080406164114700_bib93","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1136\/heartjnl-2012-301778","article-title":"Bariatric surgery and cardiovascular outcomes: a systematic review","volume":"98","author":"Vest","year":"2012","journal-title":"Heart"},{"key":"2025080406164114700_bib94","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1177\/1060028014529260","article-title":"Effect of bariatric surgery on hypertension: a meta-analysis","volume":"48","author":"Wilhelm","year":"2014","journal-title":"Ann Pharmacother"},{"key":"2025080406164114700_bib95","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1093\/ajh\/hpv153","article-title":"Predictors of hypertension remission and recurrence after bariatric surgery","volume":"29","author":"Benaiges","year":"2016","journal-title":"Am J Hypertens"},{"key":"2025080406164114700_bib96","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/joim.12012","article-title":"Review of the key results from the Swedish Obese Subjects (SOS) trial\u2014a prospective controlled intervention study of bariatric surgery","volume":"273","author":"Sjostrom","year":"2013","journal-title":"J Intern Med"},{"key":"2025080406164114700_bib97","doi-asserted-by":"publisher","first-page":"4049","DOI":"10.3390\/jcm10184049","article-title":"Bariatric surgery and hypertension","volume":"10","author":"Climent","year":"2021","journal-title":"J Clin Med"},{"key":"2025080406164114700_bib98","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s11695-008-9671-z","article-title":"Laparoscopic Roux-en-Y gastric bypass and its early effect on blood pressure","volume":"19","author":"Ahmed","year":"2009","journal-title":"Obes Surg"},{"key":"2025080406164114700_bib99","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1097\/SLA.0b013e3180caa3e3","article-title":"Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass","volume":"246","author":"le Roux","year":"2007","journal-title":"Ann Surg"},{"key":"2025080406164114700_bib100","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.1523\/JNEUROSCI.23-07-02939.2003","article-title":"Glucagon-like peptide-1-responsive catecholamine neurons in the area postrema link peripheral glucagon-like peptide-1 with central autonomic control sites","volume":"23","author":"Yamamoto","year":"2003","journal-title":"J Neurosci"},{"key":"2025080406164114700_bib101","doi-asserted-by":"publisher","first-page":"52","DOI":"10.2174\/1381612822666151119144458","article-title":"Human ghrelin: a gastric hormone with cardiovascular properties","volume":"22","author":"Virdis","year":"2016","journal-title":"Curr Pharm Dis"},{"key":"2025080406164114700_bib102","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.soard.2011.01.044","article-title":"Effects of postbariatric surgery weight loss on adipokines and metabolic parameters: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy\u2014a prospective randomized trial","volume":"7","author":"Woelnerhanssen","year":"2011","journal-title":"Surg Obes Relat Dis"},{"key":"2025080406164114700_bib103","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1161\/01.ATV.0000073313.16135.21","article-title":"Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients","volume":"23","author":"Kopp","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2025080406164114700_bib104","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1007\/s11605-012-1855-0","article-title":"Effect of Roux-en-Y gastric bypass vs sleeve gastrectomy on glucose and gut hormones: a prospective randomised trial","volume":"16","author":"Ram\u00f3n","year":"2012","journal-title":"J Gastrointest Surg"},{"key":"2025080406164114700_bib105","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.vgie.2017.01.002","article-title":"Technical aspects of endoscopic sleeve gastroplasty","volume":"2","author":"Barola","year":"2017","journal-title":"VideoGIE"},{"key":"2025080406164114700_bib106","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.cgh.2016.12.012","article-title":"Endoscopic sleeve gastroplasty significantly reduces body mass index and metabolic complications in obese patients","volume":"15","author":"Sharaiha","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025080406164114700_bib107","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cgh.2019.07.009","article-title":"Are we moving in the right direction by altering gastric motility for weight loss?","volume":"18","author":"Sharaiha","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025080406164114700_bib108","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1007\/s11695-012-0622-3","article-title":"Metabolic and hormonal changes after laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy: a randomized, prospective trial","volume":"22","author":"Peterli","year":"2012","journal-title":"Obes Surg"},{"key":"2025080406164114700_bib109","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ijsu.2018.06.038","article-title":"Incidence of nausea and vomiting after intragastric balloon placement in bariatric patients\u2014a systematic review and meta-analysis","volume":"57","author":"Trang","year":"2018","journal-title":"Int J Surg"},{"key":"2025080406164114700_bib110","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/ajg.2016.530","article-title":"The impact of intragastric balloons on obesity-related co-morbidities: a systematic review and meta-analysis","volume":"112","author":"Popov","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"2025080406164114700_bib111","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1016\/S0140-6736(21)02394-1","article-title":"Adjustable intragastric balloon for treatment of obesity: a multicentre, open-label, randomised clinical trial","volume":"398","author":"Abu Dayyeh","year":"2021","journal-title":"Lancet"},{"key":"2025080406164114700_bib112","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.cgh.2020.04.068","article-title":"Intragastric balloon placement induces significant metabolic and histologic improvement in patients with nonalcoholic steatohepatitis","volume":"19","author":"Bazerbachi","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025080406164114700_bib113","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.3390\/jcm12031126","article-title":"Updates in endoscopic bariatric and metabolic therapies","volume":"12","author":"Qureshi","year":"2023","journal-title":"J Clin Med"},{"key":"2025080406164114700_bib114","doi-asserted-by":"publisher","first-page":"e2415392\u2013","DOI":"10.1001\/jamanetworkopen.2024.15392","article-title":"Bariatric metabolic surgery vs glucagon-like peptide-1 receptor agonists and mortality","volume":"7","author":"Dicker","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2025080406164114700_bib115","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1002\/oby.23563","article-title":"Weight loss between glucagon-like peptide-1 receptor agonists and bariatric surgery in adults with obesity: a systematic review and meta-analysis","volume":"30","author":"Sarma","year":"2022","journal-title":"Obesity (Silver Spring)"},{"issue":"10S","key":"2025080406164114700_bib116","doi-asserted-by":"publisher","first-page":"S971","DOI":"10.14309\/01.ajg.0000954768.41220.8b","article-title":"S1282 Bariatric surgery vs glucagon-like peptide-1 analogues for reducing risk of major cardiovascular events: a multi-center retrospective cohort study","volume":"118","author":"Adekolu","year":"2023","journal-title":"Am J Gastroenterol"},{"issue":"10S","key":"2025080406164114700_bib117","doi-asserted-by":"publisher","first-page":"S1237","DOI":"10.14309\/01.ajg.0000956248.42228.0d","article-title":"S1652 Comparison of bariatric surgery and glucagon-like peptide-1 analogs for prevention of nonalcoholic fatty liver disease in an obese population: a large multi-center study","volume":"118","author":"Cohen","year":"2023","journal-title":"Am J Gastroenterol"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfaf218\/63712468\/sfaf218.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/18\/8\/sfaf218\/63712468\/sfaf218.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/18\/8\/sfaf218\/63712468\/sfaf218.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T10:16:51Z","timestamp":1754302611000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfaf218\/8195525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,9]]},"references-count":117,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfaf218","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,7,9]]},"article-number":"sfaf218"}}